Additional file 1: of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Virlogeux, Victor; Zoulim, Fabien; Pugliese, Pascal; Poizot-Martin, Isabelle; Valantin, Marc-Antoine; Cuzin, Lise; Reynes, Jacques; Billaud, Eric; Huleux, Thomas; Bani-Sadr, Firouze; Rey, David; Frésard, Anne; Jacomet, Christine; Duvivier, Claudine; Cheret, Antoine; Hustache-Mathieu, Laurent; Hoen, Bruno; Cabié, André; Cotte, Laurent

doi:10.6084/m9.figshare.5711506.v1

12916_2017_979_MOESM1_ESM.docx (44.4 kB)

Additional file 1: of Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

journal contribution

posted on 2017-12-18, 05:00 authored by Victor Virlogeux, Fabien Zoulim, Pascal Pugliese, Isabelle Poizot-Martin, Marc-Antoine Valantin, Lise Cuzin, Jacques Reynes, Eric Billaud, Thomas Huleux, Firouze Bani-Sadr, David Rey, Anne Frésard, Christine Jacomet, Claudine Duvivier, Antoine Cheret, Laurent Hustache-Mathieu, Bruno Hoen, André Cabié, Laurent Cotte

Appendix. Table S1. Extrapolated numbers of HIV-monoinfected patients by subgroups in France in the population under care on January 1, 2016. Table S2. Extrapolated numbers of HIV-HCV coinfected patients with detectable HCV-RNA by subgroups in France in the population under care on January 1, 2016. Table S3. Extrapolated numbers of HIV-infected patients successfully treated for HCV or after spontaneous HCV clearance by subgroups in France in the population under care on January 1, 2016. Table S4. Estimated numbers of HIV-HCV coinfected patients by subgroup in France in the HIV undiagnosed population. Table S5. Number of first HCV infection observed each year in the Dat’AIDs cohort and extended to the diagnosed HIV population in France by risk group. Table S6. Estimated numbers of HIV-HCV coinfected IVDU considering several proportions of external cases, observed reinfection rate in the Dat'AIDs cohort, and an annual treatment coverage of 30% over the next 10 years. Table S7. Estimated numbers of HIV-HCV coinfected IVDU considering several proportions of external cases, reinfection rate based on mean first infection rate observed in the Dat'AIDs cohort, and an annual treatment coverage of 30% over the next 10 years. (DOCX 44 kb)